© 2015 European Society of Cardiology. Aims: Hyperkalaemia in heart failure patients limits use of cardioprotective renin-angiotensin-aldosterone system inhibitors (RAASi). Sodium zirconium cyclosilicate (ZS-9) is a selective potassium ion trap, whose mec
Background Hyperkalaemia is a common co-morbidity in patients with heart failure with reduced ejecti...
Aims: At present, the clinical burden of hypokalaemia and hyperkalaemia among European heart failure...
Hyperkalemia contributes to significant mortality and limits the use of cardioprotective and renopro...
International audienceAIMS:Hyperkalaemia in heart failure patients limits use of cardioprotective re...
AimsHyperkalaemia in heart failure patients limits use of cardioprotective renin-angiotensin-aldoste...
Background: Sodium zirconium cyclosilicate (SZC), a newly introduced specific potassium binder, is i...
Hyperkalaemia has become an increasingly prevalent finding in patients with heart failure (HF), espe...
Heart failure (HF) is a worrisome cardiac pandemic with a negative prognostic impact on the overall ...
BACKGROUND: Sodium zirconium cyclosilicate (SZC), a newly-developed selective potassium binder, has ...
Hyperkalemia is a frequent and sometimes life-threatening condition that may be associated with arrh...
Abstract Background CKD is common in heart failure (HF) and associated with morbidity and mortality,...
Chronic kidney disease (CKD) and chronic heart failure (CHF) are two entities that share several asp...
International audienceChronic kidney disease (CKD) patients and more so CKD patients treated with re...
Background Hyperkalaemia is a common co-morbidity in patients with heart failure with reduced ejecti...
Aims: Hyperkalaemia is observed frequently in heart failure (HF) patients and is associated with an ...
Background Hyperkalaemia is a common co-morbidity in patients with heart failure with reduced ejecti...
Aims: At present, the clinical burden of hypokalaemia and hyperkalaemia among European heart failure...
Hyperkalemia contributes to significant mortality and limits the use of cardioprotective and renopro...
International audienceAIMS:Hyperkalaemia in heart failure patients limits use of cardioprotective re...
AimsHyperkalaemia in heart failure patients limits use of cardioprotective renin-angiotensin-aldoste...
Background: Sodium zirconium cyclosilicate (SZC), a newly introduced specific potassium binder, is i...
Hyperkalaemia has become an increasingly prevalent finding in patients with heart failure (HF), espe...
Heart failure (HF) is a worrisome cardiac pandemic with a negative prognostic impact on the overall ...
BACKGROUND: Sodium zirconium cyclosilicate (SZC), a newly-developed selective potassium binder, has ...
Hyperkalemia is a frequent and sometimes life-threatening condition that may be associated with arrh...
Abstract Background CKD is common in heart failure (HF) and associated with morbidity and mortality,...
Chronic kidney disease (CKD) and chronic heart failure (CHF) are two entities that share several asp...
International audienceChronic kidney disease (CKD) patients and more so CKD patients treated with re...
Background Hyperkalaemia is a common co-morbidity in patients with heart failure with reduced ejecti...
Aims: Hyperkalaemia is observed frequently in heart failure (HF) patients and is associated with an ...
Background Hyperkalaemia is a common co-morbidity in patients with heart failure with reduced ejecti...
Aims: At present, the clinical burden of hypokalaemia and hyperkalaemia among European heart failure...
Hyperkalemia contributes to significant mortality and limits the use of cardioprotective and renopro...